Sanofi Positioning Aflibercept To Compete With Genentech’s Avastin In Certain Settings
Company plans to file VEGF Trap for its first indication, ovarian cancer, in 2008, followed by second-line lung cancer and second-line colorectal cancer.
Company plans to file VEGF Trap for its first indication, ovarian cancer, in 2008, followed by second-line lung cancer and second-line colorectal cancer.